微泡
脂质体
毒品携带者
免疫原性
癌症
药物输送
生物相容性材料
化学
药品
药理学
生物
纳米技术
医学
免疫系统
生物化学
免疫学
材料科学
小RNA
生物医学工程
内科学
基因
作者
Disha N. Moholkar,Raghuram Kandimalla,Ramesh C. Gupta,Farrukh Aqil
出处
期刊:Cancer Letters
[Elsevier]
日期:2023-07-01
卷期号:565: 216220-216220
被引量:9
标识
DOI:10.1016/j.canlet.2023.216220
摘要
Cancer has recently surpassed heart disease as the leading cause of deaths worldwide for the age group 45-65 and has been the primary focus for biomedical researchers. Presently, the drugs involved in the first-line cancer therapy are raising concerns due to high toxicity and lack of selectivity to cancer cells. There has been a significant increase in research with innovative nano formulations to entrap the therapeutic payload to enhance efficacy and eliminate or minimize toxic effects. Lipid-based carriers stand out due to their unique structural properties and biocompatible nature. The two main leaders of lipid-based drug carriers: long known liposomes and comparatively new exosomes have been well-researched. The similarity between the two lipid-based carriers is the vesicular structure with the core's capability to carry the payload. While liposomes utilize chemically derived and altered phospholipid components, the exosomes are naturally occurring vesicles with inherent lipids, proteins, and nucleic acids. More recently, researchers have focused on developing hybrid exosomes by fusing liposomes and exosomes. Combining these two types of vesicles may offer some advantages such as high drug loading, targeted cellular uptake, biocompatibility, controlled release, stability in harsh conditions and low immunogenicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI